Literature DB >> 19200302

Characteristics of immune thrombocytopenic purpura: a guide for clinical practice.

Drew Provan1.   

Abstract

Immune (idiopathic) thrombocytopenic purpura (ITP) is an autoantibody-mediated condition characterized by an abnormally low number of platelets in the circulating blood. Originally, the cause of ITP was attributed to accelerated antibody-mediated platelet destruction where the rate of thrombopoiesis was inadequate to offset the increased rate of platelet destruction. However, new evidence has indicated that insufficient or inadequate platelet production is also responsible for low platelet counts, and research has focused on the development of treatments that increase platelet production. ITP affects both children and adults and can be either acute or chronic. To manage and treat ITP effectively, an exhaustive assessment of the signs and symptoms must be undertaken because the clinical manifestation of ITP can be highly variable among patients. At the moment, the diagnostic approach in ITP is based largely on a process of exclusion due to the lack of available data regarding clinical and laboratory parameters. The diagnostic procedures used in children and adults are similar and involve collecting the patient's history and performing a physical examination. Laboratory investigations are kept simple in patients with suspected ITP and include a full blood count and peripheral blood smear. A number of specialized laboratory assays have been developed with varying degrees of success. There remains scope for improving and simplifying the diagnostic process to identify ITP.

Entities:  

Mesh:

Year:  2009        PMID: 19200302     DOI: 10.1111/j.1600-0609.2008.01207.x

Source DB:  PubMed          Journal:  Eur J Haematol Suppl        ISSN: 0902-4506


  6 in total

Review 1.  Immune thrombocytopenic purpura (ITP) associated with vaccinations: a review of reported cases.

Authors:  Carlo Perricone; Fulvia Ceccarelli; Gideon Nesher; Elisabetta Borella; Qasim Odeh; Fabrizio Conti; Yehuda Shoenfeld; Guido Valesini
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

2.  Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial.

Authors:  Yukari Shirasugi; Kiyoshi Ando; Koji Miyazaki; Yoshiaki Tomiyama; Shinichiro Okamoto; Mineo Kurokawa; Keita Kirito; Yuji Yonemura; Shinichiro Mori; Kensuke Usuki; Koji Iwato; Satoshi Hashino; Helen Wei; Richard Lizambri
Journal:  Int J Hematol       Date:  2011-06-25       Impact factor: 2.490

3.  Immune thrombocytopenic purpura might be an early hematologic manifestation of undiagnosed human immunodeficiency virus infection.

Authors:  Shih-Wei Lai; Hsien-Feng Lin; Cheng-Li Lin; Kuan-Fu Liao
Journal:  Intern Emerg Med       Date:  2016-08-25       Impact factor: 3.397

4.  Systematic literature review of treatments used for adult immune thrombocytopenia in the second-line setting.

Authors:  Lauren C Bylsma; Jon P Fryzek; Karynsa Cetin; Fiona Callaghan; Carla Bezold; Bhakti Mehta; Jeffrey S Wasser
Journal:  Am J Hematol       Date:  2018-10-21       Impact factor: 10.047

5.  Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease.

Authors:  Leslie P Cousens; Federico Mingozzi; Sander van der Marel; Yan Su; Richard Garman; Valerie Ferreira; William Martin; David W Scott; Anne S De Groot
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

Review 6.  Current Management of Primary Immune Thrombocytopenia.

Authors:  Drew Provan; Adrian C Newland
Journal:  Adv Ther       Date:  2015-10-26       Impact factor: 3.845

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.